跳至主要内容
临床试验/NCT00295009
NCT00295009已完成不适用

A Multi-Center, Prospective, Randomized, Controlled Clinical Trial Comparing the Safety and Effectiveness of ProDisc to Spinal Fusion Surgery in the Treatment of Discogenic Pain Associated With DDD in the Lumbosacral Spine

Synthes USA HQ, Inc.0 个研究点目标入组 852 人开始时间: 2001年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
852
主要终点
Overall Success

研究概览

简要总结

The objective of this clinical investigation is to compare the safety and effectiveness of ProDisc total disc replacement to spinal fusion surgery in the treatment of discogenic pain associated with DDD in the lumbosacral spine. There will be separate study arms for one and two level cases.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Degenerative Disc Disease (DDD) in one or two adjacent vertebral levels between L3 and S
  • Diagnosis of DDD requires: a)Back and/or leg (radicular) pain; and b)Radiographic confirmation of any 1 of the following by CT, MRI, discography, plain film, myelography and/or flexion/extension films: Instability (greater than or equal to 3mm translation or 5° angulation); Decreased disc height >2mm; Scarring/thickening of annulus fibrosis; Herniated nucleus pulposus; or Vacuum phenomenon.
  • Age between 18 and 60 years.
  • Failed at least 6 months of conservative treatment.
  • Oswestry Low Back Pain Disability Questionnaire score of at least 20/50 (40%)(Interpreted as moderate/severe disability).
  • Psychosocially, mentally and physically able to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms.
  • Signed informed consent.

排除标准

  • No more than 2 vertebral levels may have DDD and all diseased levels, either one or two, must be treated.
  • Patients with involved vertebral endplates dimensionally smaller than 34.5mm in the medial-lateral and/or 27mm in the anterior-posterior directions.
  • Known allergy to titanium, polyethylene, cobalt, chromium, or molybdenum.
  • Prior fusion surgery at any vertebral level.
  • Clinically compromised vertebral bodies at the affected level(s) due to current or past trauma.
  • Radiographic confirmation of facet joint disease or degeneration.
  • Lytic spondylolisthesis or spinal stenosis.
  • Degenerative spondylolisthesis of grade >
  • Back or leg pain of unknown etiology.
  • Osteopenia or Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients to determine if a DEXA scan is required. If DEXA is required, exclusion will be defined as a DEXA bone density measured T score less than
  • The World Health Organization defines osteoporosis as a DEXA T score less than or equal to -2.
  • Paget's disease, osteomalacia or any other metabolic bone disease (excluding osteoporosis which is addressed above).
  • Morbid obesity defined as a body mass index >40 or a weight more than 100 lbs. over ideal body weight.
  • Pregnant or interested in becoming pregnant in the next 3 years.
  • Active infection - systemic or local.
  • Taking medication or any drug known to potentially interfere with bone/soft tissue healing (e.g., steroids).
  • Rheumatoid arthritis or other autoimmune disease.
  • Systemic disease including AIDS, HIV, Hepatitis.
  • Active malignancy: A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there has been no clinical signs or symptoms of the malignancy for at least 5 years.

结局指标

主要结局

Overall Success

时间窗: 60 Months

Overall success was a composite endpoint. A ProDisc patient was considered an overall success if, and only if, ALL of the following criteria were met: 1. ODI score improved by at least 15% from baseline; 2. SF-36 score improved from baseline; 3. Neurologic parameters maintained or improved from baseline; 4. No re-operations required to modify or remove the implant; and 5. Independent radiographic review confirmed no migration/subsidence, radiolucency, loss of disc height, loss of range of motion, or boney fusion. A Fusion patient was a considered to be a success if, and only if, ALL of the following criteria were met: Items numbered 1-3, above; 4. No re-operations required to modify the fusion site or correct a complication with an implant; and 5. Independent radiographic review confirmed strong evidence of fusion and no motion, visible gaps in fusion mass, loss of disc height, migration/subsidence, implant loosening, halos, or radiolucencies

次要结局

未报告次要终点

研究者

发起方
Synthes USA HQ, Inc.
申办方类型
Industry
责任方
Sponsor

相似试验